« Roche Weathers Tough Year - Looks to Pipeline in 2011 | Main | In the Pipeline looks at Pfizer/Merck R&D Forked Paths Taken »

02/03/2011

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0147e2452984970b

Listed below are links to weblogs that reference Pfizer and Merck Take Opposite Tack on R&D vs EPS:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

I agree that just spending money whether it be on baseball free agents, school teacher salaries or pharma R&D doesn't guarantee success. And, a model that incorporates both internal R&D and in-licensing may work well. Time/the market will tell us if Pfizer has th emix correct or not.

Biotechtweet

R&D budgets are one thing, but we all realise by now that innovation is not working at big .
Pfizer have a very innovative model that allows late stage development teams to select compounds to develop, and they realise that this are not going to come from internal research efforts.
So we need to know what these companies are spending on in licensing and developing innovation from biotech to get a better picture

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada